医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B Financing

2018年08月08日 PM10:00
このエントリーをはてなブックマークに追加


 

BEIJING & CAMBRIDGE, Mass.

EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of approximately $15 Million in a Series pre-B financing.

The financing is led by new investor Lilly Asia Ventures (LAV). New investor Huagai Capital participated in this round. Series A lead investor IDG Capital, Series A investor WI Harper Group and other insiders also participated in this round.

“This investment will allow us to continue advancing our promising portfolio of therapeutic programs based on gene-editing technologies,” said Dr. Dong Wei, CEO of EdiGene, “In addition, we will continue to further develop our proprietary High Throughput Genome Screening platforms into a comprehensive solution for our partners in key areas such as drug sensitivity, drug resistance and synthetic lethality.”

“We are excited to invest in EdiGene,” said Dr. Fei Chen, Managing Partner of Lilly Asia Ventures, “Gene editing is bringing evolutional breakthrough to drug discovery and potential clinical therapeutics, and we are pleased to collaborate with EdiGene team and to support EdiGene’s growth in the global market.”

“This new round of financing led by Lilly Asia Ventures with participation of new and existing investors further validates the progress we have made and the potential of our platforms,” said Dr. Wensheng Wei, founder of EdiGene. “Now we are well positioned to further advance our pipeline and get one step closer to help patients with our technologies. We look forward to working with Lilly Asia Ventures and other investors for the years to come.”

About EdiGene, Inc

EdiGene Inc is founded in 2015, and now headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA. Our mission is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery. We leverage our proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts.

About Lilly Asia Ventures (LAV)

Founded in 2008 and headquartered in Shanghai, LAV is a leading VC firm investing in the biomedical, pharmaceutical and medical devices/diagnostics industries in China and US. LAV provides early-to-growth-stage companies with wise capital, professional expertise and valuable resources. LAV has offices in northern California, Shanghai and Hong Kong.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180808005378/en/

CONTACT

EdiGene Inc.
Meng Wang, +86 10-80733899
Media@edigene.com
www.edigene.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作